Molecular fields in ligand discovery.

Methods Mol Biol

Medicinal Chemistry, Wolfson Institute for Biomedical Research, University College London, London, UK.

Published: December 2013

The discovery of novel biologically active small molecules is now a technologically and economically viable proposition for academic and small biotechnology laboratories wishing to build on their biological research into target proteins. Such small molecules may be useful reagents for further biological research or may form the basis for early-stage drug discovery. The availability of specialized virtual screening software to filter large molecular libraries into manageable numbers of compounds for biological assays is the driving force for finding novel ligands. The main focus of this chapter is the basis and use of molecular field methods to assess the interactions that may be made by small molecules. Molecular field based measures of capability and similarity of interaction may be used to discover novel ligands and expand ligand series for potential use as future therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-398-5_18DOI Listing

Publication Analysis

Top Keywords

small molecules
12
novel ligands
8
molecular field
8
molecular
4
molecular fields
4
fields ligand
4
ligand discovery
4
discovery discovery
4
discovery novel
4
novel biologically
4

Similar Publications

CDK1 inhibitor RO-3306 enhances BTKi potency in diffuse large B-cell lymphoma by suppressing JAK2/STAT3 signaling.

Int J Biol Macromol

January 2025

Department of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian 223300, Jiangsu Province, PR China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, PR China. Electronic address:

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in adults, which characterized by a high degree of heterogeneity in terms of clinical presentation, molecular phenotype, and genetic features. However, approximately 30 %-40 % of patients are refractory to standard chemotherapy, and their prognosis is poor. The emergence of small-molecule inhibitors, such as Bruton's tyrosine kinase inhibitors (BTKi), has greatly improved the treatment of DLBCL; however, drug resistance associated with small-molecule inhibitors has greatly limited their clinical application.

View Article and Find Full Text PDF

The riverine dissolved organic matter (DOM) pool constitutes the largest and most dynamic organic carbon reservoir within inland aquatic systems. Human activities significantly alter the distribution of organic matter (OM) in rivers, thereby affecting the availability of DOM. However, the impact of total suspended solids (TSS) on DOM under anthropogenic influence remains insufficiently elucidated.

View Article and Find Full Text PDF

This paper introduces a highly absorbent and sensitive cellulose nanofiber (CNF)/gold nanorod (GNR)@Ag surface-enhanced Raman scattering (SERS) sensor, fabricated using the vacuum filtration method. By optimizing the Ag thickness in the GNR@Ag core-shell structures and integrating them with CNFs, optimal SERS hotspots were identified using the Raman probe molecule 4-aminothiophenol (4-ATP). To concentrate pesticides extracted from fruit and vegetable surfaces, we utilized the evaporation enrichment effect using hydrophilic CNF and hole-punched hydrophobic polydimethylsiloxane (PDMS).

View Article and Find Full Text PDF

Discovery of CZY43 as a new small-molecule degrader of pseudokinase HER3.

Eur J Med Chem

January 2025

State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, #345 Lingling Rd, Shanghai, 200032, China. Electronic address:

The pseudokinase HER3 emerges as a promising anti-cancer target, especially for HER2-driven breast cancer and EGFR-mediated non-small cell lung cancer. However, it is challenging to target HER3 by ATP-competitive small molecules because HER3 is catalytically impaired. Herein, we report the discovery of a series of HER3 degraders by connecting a HER3 binder bosutinib with a hydrophobic tag adamantane.

View Article and Find Full Text PDF

Peptide-based PET/CT imaging visualizes PD-L1-driven radioresistance in glioblastoma.

Drug Resist Updat

January 2025

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China. Electronic address:

Radioresistance remains a great challenge for radiotherapy in the treatment of glioblastoma (GBM). PD-L1 expression is a key contributor to radioresistance and immune escape in GBM. The lack of effective methods to monitor the change of PD-L1 during radiotherapy in patients limits timely intervention and management of the resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!